Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
NCT ID: NCT00180817
Last Updated: 2022-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
250 participants
OBSERVATIONAL
1998-09-30
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
NCT00180778
Antiphospholipid Antibodies and Early Severe Preeclampsia.
NCT01538121
The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations
NCT02855047
Evaluation of Apelin-13 and Apelin-36 in Women With Recurrent Pregnancy Loss
NCT05205044
AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
NCT03100123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imperial College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lesley Regan
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Raj Rai, MRCOG
Role: PRINCIPAL_INVESTIGATOR
Imperial College London
Winnie Lo
Role: PRINCIPAL_INVESTIGATOR
St. Mary's NHS Trust, London
Preeti Jindal, MRCOG
Role: PRINCIPAL_INVESTIGATOR
St. Mary's NHS Trust, London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Mary's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EC3103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.